Publications by authors named "E Brissot"
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Jesús Duque-Afonso Jürgen Finke Maud Ngoya Jacques-Emmanuel Galimard Johannes Schetelig Eolia Brissot
Bone Marrow Transplant
December 2024
The treatment of relapsed/refractory acute myeloid leukemia (AML) is associated with a dismal prognosis. The allogeneic hematopoietic cell transplantation (allo-HCT) is frequently performed as salvage therapy. Reduced intensity conditioning protocols have been developed with the aim of reducing the leukemia burden without increasing their toxicity.
View Article and Find Full Text PDFArticle Synopsis
- - Immune effector cell-associated hematotoxicity (ICAHT) is a significant and common side effect following CAR-T-cell therapy, particularly impacting patient recovery and health.
- - The article discusses three cases where patients experienced severe ICAHT after receiving axicabtagene-ciloleucel (axi-cel) for diffuse large B-cell lymphoma, characterized by an increase in a specific type of lymphocyte in the bone marrow.
- - Treatment with low-dose steroids successfully resolved the cytopenias (low blood cell counts) without harming the effectiveness of the cancer treatment.
Purpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL.
Patients And Methods: EWALL-INO is an open-label prospective multicenter phase II trial (ClinicalTrials.gov identifier: NCT03249870).
Article Synopsis
- * A significant number of respondents (67.0%) felt that early diagnosis was challenging, but many (75.8%) found the new 2023 EBMT diagnostic criteria useful and easy to apply.
- * Key risk factors for VOD/SOS included second allo-HCT, pre-existing liver disease, and prior use of antibody-drug conjugates, with varied preferences on when to start treatment.